Platinum sponsor

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases such as diabetes, obesity, cardiovascular diseases and rare blood disorders. We have affiliates in 80 countries, serving almost 40 million patients globally, with total net sales of 177 billion DKK (roughly 186 billion CNY) in 2022.

Deeply rooted in China for the past 29 years, Novo Nordisk has been expanding our investment to continuously deepen our local presence covering the full value chain, i.e. R&D, production and operation in China. The “Dual Centres, Triple Engines” strategic layout in Beijing, Shanghai and Tianjin enables us to better serve Chinese patients.

NNRCC, founded in 1997, takes pride in being the first research centre established by a multinational pharmaceutical company in China. Located in Zhongguancun Life Science Park, our state-of-the-art facilities cover 18,000 square metres. Tapping into the wealth of opportunities and talents in biomedical sciences in China, NNRCC strives to be a world class research centre in innovative drug discovery, forging collaborations and facilitating translational research in China.

Focusing on novel target discovery and protein / peptide drug research, NNRCC has fully fledged capabilities and rich experiences in relevant areas, from early-stage target identification and validation, drug candidate selection and optimisation, to preclinical pharmacology (PK). Being an essential part of Novo Nordisk global R&D endeavours, NNRCC takes part in a large number of drug research projects in areas of diabetes, obesity, atherosclerosis, NASH and chronic kidney disease etc.

In March 2019, NNRCC launched INNOVO®, an open innovation platform, as we gear up for increased research collaborations with dynamic innovation forces in China, building a new pharmaceutical innovation ecosystem and contributing to research pipelines locally and globally. By far, INNOVO® has established diverse partnerships among universities, biotech companies, hospitals, research institutes and consortium etc, spanning a number of areas, such as diabetes, obesity, cardiovascular disease, NASH, AI in drug research, cell therapy and other novel technologies.

Website: https://www.novonordisk.com.cn/

诺和诺德中国研发中心
诺和诺德于1923年在丹麦建立，是世界领先的医药公司之一。我们的使命是驱动改变，携手战胜糖尿病和其他严重慢性疾病。诺和诺德在80个国家和地区设有分支机构，为全球接近4千万患者提供服务。2022年总收入达1770亿丹麦克朗（约1860亿人民币）。

在过去的29年中，诺和诺德植根中国，持续加码投资，深化全产业链布局，涵盖研发、运营与生产环节。通过在北京、上海、天津的“双中心，三引擎”战略布局，更好地服务中国患者。

诺和诺德中国研发中心成立于1997年，是首家由跨国医药公司在华设立的研发中心，位于北京中关村生命科学园，设施占地面积约18000平方米。诺和诺德中国研发中心依托于中国高速发展的生物医药科技带来的良性生态和人才优势，打造世界一流水准的药物发现中心，促进合作，助力转化研究。

目前，诺和诺德中国研发中心专注于创新靶点发现与治疗性蛋白及多肽类药物研究，拥有从早期药物靶点发现、验证，到候选药物分子筛选、优化，及临床前药代药理测试、评估的完善能力和丰富经验。 研发中心参与公司在糖尿病、肥胖症、心血管疾病、非酒精性脂肪性肝炎、慢性肾病等领域众多新药研究项目，是诺和诺德全球研发体系的重要组成部分。

为了更加积极探索在中国的研发合作机遇，诺和诺德中国研发中心于2019年3月发起成立了INNOVO®开放创新平台，携手最具活力的中国本土创新力量，搭建医药开放创新合作的新生态，为中国及全球的研发管线做出贡献。INNOVO®合作伙伴来自院校、生物科技公司、医院、科研机构和联盟等；涵盖多个领域，包括糖尿病、肥胖症、心血管疾病、非酒精性脂肪性肝炎、人工智能辅助的新药研发、细胞疗法以及其他新兴技术的探索。

« Go Back